Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS with relapses who completed study 3066A2-210-WW.
Inclusion criteria
- Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)